How Will Recent Safety Concerns Affect PPAR-Gamma Agonists?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• An Overview of PPAR-Gamma Agonists
  • Mechanism of Action
  • Side Effects of PPAR-Gamma Agonists
  • PPAR-Gamma Agonists in the Treatment of Type 2 Diabetes
  • PPAR-Gamma Agonists in the Type 2 Diabetes Market
• The Controversy Surrounding Avandia
  • New Concerns Arise Over Avandia Use
  • Response and Repercussions
  • Are the Cardiovascular Risks a Class Effect?
• Do Avandia' s Safety Concerns Represent a Commercial Opportunity?
  • The Incretin Pathway
  • Eli Lilly/Amylin' s Byetta
  • Merck' s Januvia
• Outlook for PPAR-Gamma Agonists and the Type 2 Diabetes Market

Sidebar/Expert Commentary

• How Important Is Avandia to GlaxoSmithKline?
• Greater Transparency Needed for Clinical Trial Results

Tables

• 1. Results from Large-Scale Trials Involving Avandia

Figures

• 1. Mechanism of Action for PPAR-Gamma Agonists
• 2. Worldwide Sales of PPAR-Gamma Agonists, 1999-2006
• 3. Results from a Meta-Analysis of Trials Involving Avandia
• 4. Incretin Pathway
• 5. Growth of Key Drug Classes in the Type 2 Diabetes Market, 1999-2006
• 6. Comparison of Sales for Actos and Avandia, 1999-2006